Showing 4941-4950 of 5291 results for "".
- InMed Initiates Program Targeting Epidermolysis Bullosa Simplexhttps://practicaldermatology.com/news/inmed-initiates-program-targeting-epidermolysis-bullosa-simplex/2459014/InMed Pharmaceuticals Inc. added a new therapy to its pipeline: INM-750, for the treatment of Epidermolysis bullosa simplex(EBS), a rare genetically inherited skin disorder. INM-750 is designed to suppress pathological skin growth, differentiation, and inflammation that are signature characterist
- Alphaeon Begins Phase III Study For Its Neurotoxin, Evosyalhttps://practicaldermatology.com/news/alphaeon-begins-phase-iii-study-for-its-neurotoxin-evosyal/2459018/The FDA agreed to Alphaeon® Corporations’s protocol for its Phase III clinical study of Evosyal™ to treat glabellar lines. Alphaeon acquired the exclusive US and certain international distribution rights to Evosyal, a botulinum toxin type A neuromodulator, as part of it
- ASDSA Names 2014 Patient Safety Hero Award Winnershttps://practicaldermatology.com/news/asdsa-named-2014-patient-safety-hero-award-winners/2459025/Honoring physicians and dermatologic societies whose notable efforts for greater patient safety in cosmetic procedures have made a difference last year, the American Society for Dermatologic Surgery Association (ASDSA) recently named the 2014 winners of its an
- Dermira and UCB Announce Start of Phase 3 Program for Cimzia® (Certolizumab Pegol) in Psoriasishttps://practicaldermatology.com/news/dermira-and-ucb-announce-start-of-phase-3-program-for-cimzia-certolizumab-pegol-in-psoriasis/2459027/Dermira, Inc., a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients (NASDAQ: DERM), and UCB, a global biop
- Suneva Medical's Bellafill Approved to Treat Acne Scarshttps://practicaldermatology.com/news/suneva-medicals-bellafill-approved-to-treat-acne-scars/2459034/Suneva Medical, Inc.'s Bellafill® is now the only filler on the market approved for the treatment of acne scars. FDA granted approval for Bellafil
- Vivacare Launches "Find a Dermatologist" Directory with "Expert Opinion" Functionhttps://practicaldermatology.com/news/vivacare-launches-find-a-dermatologist-directory-with-expert-opinion-function/2459044/Vivacare has launched its new <a href="http://www.findadermatologist.com" target="_blank">Find a Dermatolog
- The Cetaphil Brand Launches New Cetaphil Baby Linehttps://practicaldermatology.com/news/the-cetaphil-brand-launches-new-cetaphil-baby-line/2459050/Galderma Laboratories, L.P., makers of Cetaphil, launched Cetaphil Baby, a line designed with babies and parents in mind. Cetaphil Baby is formulated with ingredients like organic calendula, almond oil and sunflower oil to soothe sensitive and irritated skin. All Cetaphil Baby products are
- Cetaphil Brand Revamps RestoraDerm Product Linehttps://practicaldermatology.com/news/20141117-cetaphil_brand_revamps_restoraderm_product_line/2459061/Galderma Laboratories, LP unveiled a new and improved look for their Cetaphil RestoraDerm product line. The new look brings eczema to the forefront of the packaging featuring their new names, Cetaphil RestoraDerm Eczema Calming Body Wash and Cetaphil RestoraDerm Eczema Calming M
- Zeltiq Named Top Medical Devices Company in Deloitte's Technology Fast 500™https://practicaldermatology.com/news/20141117-zeltiq_named_top_medical_devices_company_in__deloittes_technology_fast_500/2459063/Ranked among the top 25 companies in Deloitte's Technology Fast 500™ ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America, Zeltiq Aesthetics, Inc. is the top ranked
- Oculus Innovative Sciences Commercializes Microcyn-Based Solution and Hydrogel for Treatment of Mild-to-Moderate Acne in Europehttps://practicaldermatology.com/news/20141113-oculus_innovative_sciences_commercializes_microcyn-based____solution_and_hydrogel_for_treatment_of_mild-to-moderate_acne_in_europe/2459068/Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care in 37 countries, today announced the European commercialization of Microcyn(R)-based GramaDerm(TM) Solution a